When was Boost Neuroscience founded?

Boost Neuroscience was founded in 2020.

Where is Boost Neuroscience located?

Boost Neuroscience is located in Menlo Park, United States .

Where does Boost Neuroscience rank among its competitors?

Boost Neuroscience ranks 514 amongst 436 active competitors.

Who are the top competitors of Boost Neuroscience?

Boost Neuroscience's top competitors are Jazz Pharmaceuticals, Neurocrine and Intra-Cellular Therapies.

Boost Neuroscience - 2025 Company Profile & Competitors - Tracxn

Boost Neuroscience is an acquired company based in Menlo Park (United States), founded in 2020 by Thomas Sudhof, Matt Pando, Avram Goldstein and Nobel Laureate. It operates as a Developer of therapeutics for the treatment of CNS disorders. The company has 436 active competitors, including 146 funded and 104 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Neurocrine and Intra-Cellular Therapies.

Company Details

Developer of therapeutics for the treatment of CNS disorders. The company discover and develop classes of therapeutics that promote synaptic health and function to combat a wide array of CNS diseases.

Key Metrics

Founded Year

2020

Location

Menlo Park, United States

Stage

Acquired

Ranked

514^th among 514 competitors

Similar Companies

Jazz Pharmaceuticals & 512 more

Exit Details

Acquired by Gate Neurosciences (Feb 19, 2025)

Boost Neuroscience got acquired by Gate Neurosciences on Feb 19, 2025.

Click here to take a look at Boost Neuroscience's acquisition in detail

Boost Neuroscience has not raised any funding rounds yet.

The founders of Boost Neuroscience are Thomas Sudhof, Matt Pando, Avram Goldstein and Nobel Laureate.

View details of Boost Neuroscience's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Boost Neuroscience include Jazz Pharmaceuticals, Neurocrine and Intra-Cellular Therapies. Here is the list of Top 10 competitors of Boost Neuroscience, ranked by Tracxn score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Oak Hill, InterWest Partners & 14 others	80/100
2nd	Neurocrine 1992, San Diego (United States), Public	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	BB Biotech, International Biotechnology Trust & 5 others	69/100
3rd	Intra-Cellular Therapies 2002, New York City (United States), Acquired	Developer of therapeutics for psychiatric and neurologic diseases	$80.9M	BB Biotech, International Biotechnology Trust & 5 others	69/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	BB Biotech, Athyrium Capital Management & 25 others	68/100
5th	Biohaven Pharmaceutical 2014, New Haven (United States), Acquired	Developer of therapies targeting neurological and neuropsychiatric diseases	$84.1M	Aisling Capital, International Biotechnology Trust & 12 others	67/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	CPP Investments, HTIF & 17 others	67/100
7th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Ridgeback Capital Management, Tekla Capital Management & 9 others	66/100
8th	AskBio 2001, Durham (United States), Acquired	Provider of gene and protein therapies to treat various diseases	$235M	TPG, Golden Valley Capital & 4 others	65/100
9th	Acorda 1995, Ardsley (United States), Acquired	Engaged in the development and commercialization of therapies that improve neurological function.	$66.5M	Ridgeback Capital Management, Vermögensclub & 14 others	65/100
10th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Citadel, Arch Venture Partners & 18 others	65/100
514th	Boost Neuroscience 2020, Menlo Park (United States), Acquired	Developer of therapeutics for the treatment of CNS disorders	-	-	-